Companies

See how salaries can vary from company to company

Seniors and Baby Boomers - the most valuable generations in the history of marketing. Recognizing that this current generation of retirees is the most affluent ever and the first to have a significant on-line and mobile presence, Pipeline made the strategic decision to focus primarily on this growing yet fragmented market over 7 years ago. Pipeline in one of the largest providers in the U.S. of consumer's looking for senior care facilities and in-home care. We also market other related products and services that this demographic requires. Recently, we have launched a new service providing care... view company details

view company details

view company details

view company details

G-III Apparel Group, Ltd. designs, manufactures, and markets women's and men's apparel. The company's products include outerwear, dresses, sportswear, swimwear, women's suits, and women's performance wear. It also markets footwear and accessories, such as luggage, women's handbags, small leather goods, and cold weather accessories. The company markets its apparel and other products under proprietary brands, including the Bass, G.H. Bass, Vilebrequin, Andrew Marc, Marc New York, Jessica Howard, Eliza J, Black Rivet, Wilsons G-III Sports by Carl Banks, and G-III for Her, as well as under various... view company details

Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder. The company is also developing AXS-07, which is in Phase III clinical trial for the treatment of migraine; AXS-12 that... view company details

Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. The company's product pipeline includes FCD105 and FMX109 fo... view company details

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. It provides ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. The company's development programs include Vutrisiran, an investigational RNAi therapeutic targeti... view company details

Ayers Career College has been preparing men and women in the Louisiana and Texas areas for successful and in-demand careers since 1953. With six decades worth of history training students for new careers, we are one of the oldest and longest-serving Shreveport colleges today. Our programs include: Pharmacy Technician, Medical Assistant, HVAC Technician, and Information Technology Specialist. view company details

Recro Pharma, Inc. operates as a specialty pharmaceutical company. It operates through two divisions, an Acute Care, and Contract Development and Manufacturing (CDMO). The Acute Care division primarily focuses on developing products for the hospital and other acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has completed two pivotal Phase III clinical efficacy trials, a double-blind placebo-controlled Phase III safety trial, and four Phase II clinical efficacy trials, as well as oth... view company details

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia; and Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is also developing small-molecule pipeline comprising UX007, a synthetic triglyceri... view company details

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and sleep disorders; and SAGE-324, a novel neuroactive steroid... view company details

Agile Therapeutics, Inc., a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to ... view company details

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed ... view company details

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer and other diseases in North America, Europe, and the Asia Pacific. It provides BRAFTOVITM (encorafenib) capsules in combination with MEKTOVI (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF mutation. The company's lead clinical programs include encorafenib and binimetinib that are investigated in approximately 30 clinical trials for various solid tumor indications, including ... view company details

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors. The company is also developing Dalcinonacog alfa, a Factor IX drug, which has completed enrollment of a Phase I/II subcutaneous dosing trial for the prophylactic treatment of individuals with hemophilia B; CB 2679d-GT, a FIX gene therapy for the treatment ... view company details

MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3; MGA012, an anti-PD-1 monoclonal antibody, which inhibits programmed cell death protein 1 (PD-1); MGD013, a monoclonal antibody that tar... view company details

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate is Tonmyar (TNX-102 SL), a proprietary low-dose cyclobenzaprine and sublingual tablet as a bedtime administration, which is in Phase III development for the treatment of posttraumatic stress disorder (PTSD) and Fibromyalgia; and Phase II development for the treatment of agitation in Alzheimer's disease. The company is also developing TN... view company details

Aircraft Maintenance Technician (AMT), refers to a licensed qualification for carrying out aircraft maintenance. Aircraft Maintenance Technicians (AMTs) inspect and perform or supervise maintenance, preventive maintenance, and alteration of aircraft and aircraft systems. In the USA, for a person who holds a mechanic certificate issued by the Federal Aviation Administration; the rules for certification, and for certificate-holders, are detailed in Subpart D of Part 65 of the Federal Aviation Regulations (FARs), which are part of Title 14 of the Code of Federal Regulations. The US licensed qual... view company details

Halozyme Therapeutics, Inc., a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. The company's products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal ... view company details